August Editorial & News & Patents

2024-08-26 22:11   英国  

Editorial
Slaughter-free meat hits the grocery shelf
As cultivated meat begins to enter grocery stores, governments should promote the field’s development in line with broad public goals of sustainability and accessibility.
原文链接 https://www.nature.com/articles/s41587-024-02373-2 
News
1. A new class of mRNA drugs targets poison exons
Companies are targeting poison exons embedded in mRNA transcripts as a strategy to restore wild-type protein abundance and cell fitness in severe pediatric epilepsy and other genetic diseases.

原文链接 https://www.nature.com/articles/s41587-024-02355-4 

Drugging premature termination codons can tune protein production up or down. Credit: Science Photo Library / Alamy Stock Photo

2. Biotechs take multiplexing into animal models to accelerate drug discovery

Companies are moving therapeutic testing from plastic wells into pooled in vivo screening, generating physiologically relevant data by screening many drug candidates at once in a single animal.

原文链接 https://www.nature.com/articles/s41587-024-02361-6 

Testing therapies in living animals has so far been slow and expensive. Credit: Maximilian Buzun / Alamy Stock Photo

3. Spanish tortillas go vegan

原文链接 https://www.nature.com/articles/s41587-024-02366-1 

Credit: nito / Alamy Stock Photo

News in Brief
1. World’s first tax on cows

原文链接 https://www.nature.com/articles/s41587-024-02367-0 

2.  Microbes: next-generation fertilizers

原文链接 https://www.nature.com/articles/s41587-024-02368-z 
3. HIV drug 100% protective
原文链接 https://www.nature.com/articles/s41587-024-02369-y 
4. Biotech news from around the world
原文链接 https://www.nature.com/articles/s41587-024-02362-5 

News Feature

1. Editor’s pick: Unnatural Products
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Unnatural Products is rewriting the rules for potent oral therapies.

原文链接 https://www.nature.com/articles/s41587-024-02286-0 

Cameron Pye. Credit: Unnatural Products

2. Editor’s pick: Empress Therapeutics

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year.  Empress Therapeutics is reverse-engineering microbial manufacturing.

原文链接 https://www.nature.com/articles/s41587-024-02314-z 

Empress founding team (left to right): John Mendlein, executive partner, Flagship Pioneering; Sabrina Yang, chief innovation officer and co-founder, Empress Therapeutics and principal, Flagship Pioneering; Doug Cole, general partner, Flagship Pioneering; Jason Park, CEO and co-founder, Empress Therapeutics and operating partner, Flagship Pioneering. Credit: Empress Therapeutics

3. Editor’s pick: Indapta Therapeutics

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.
原文链接 https://www.nature.com/articles/s41587-024-02334-9 

Stefanie Mandl Credit: Indapta Therapeutics

Patents
1. The patentability and bioethics of molecular de-extinction
The resurrection of strings of extinct molecules raises intriguing questions of patentability and bioethical considerations in an emerging area of patent law.
原文链接 https://www.nature.com/articles/s41587-024-02332-x 
2. Single-cell analysis
Recent patents relating to compositions, methods and systems for single-cell analysis. 
原文链接 https://www.nature.com/articles/s41587-024-02337-6  

版权声明:中文内容仅供参考,一切内容以英文原版为准,欢迎转发至朋友圈。未经允许,请勿转载。未经授权的翻译是侵权行为,版权方将保留追究法律责任的权利。

© 2024 Springer Nature Limited. All Rights Reserved. 

欢迎点赞,在看+转发!

NBiotechnology
Nature Biotechnology 《自然生物技术》期刊致力于服务科学界,探索尖端科技与生命科学的交汇之处。 我们将涵盖生物学, 生物医学, 农业和环境领域,为相关最新研究成果的发布提供平台。《自然生物技术》期刊成立于1996年。
 最新文章